Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
BIVV's Cash-to-Debt is ranked higher than
61% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. BIVV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
BIVV' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.73
BIVV's Equity-to-Asset is ranked higher than
56% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIVV: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
BIVV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.73  Med: 0.75 Max: 0.81
Current: 0.73
0.73
0.81
Interest Coverage No Debt
BIVV's Interest Coverage is ranked lower than
52% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIVV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BIVV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 22.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 35.44
BIVV's Operating Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. BIVV: 35.44 )
Ranked among companies with meaningful Operating Margin % only.
BIVV' s Operating Margin % Range Over the Past 10 Years
Min: -267.93  Med: 17.49 Max: 35.44
Current: 35.44
-267.93
35.44
Net Margin % 46.31
BIVV's Net Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. BIVV: 46.31 )
Ranked among companies with meaningful Net Margin % only.
BIVV' s Net Margin % Range Over the Past 10 Years
Min: -268.08  Med: 19.38 Max: 49.54
Current: 46.31
-268.08
49.54
ROE % 113.38
BIVV's ROE % is ranked higher than
99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. BIVV: 113.38 )
Ranked among companies with meaningful ROE % only.
BIVV' s ROE % Range Over the Past 10 Years
Min: -245.27  Med: 32.01 Max: 113.38
Current: 113.38
-245.27
113.38
ROA % 84.69
BIVV's ROA % is ranked higher than
99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. BIVV: 84.69 )
Ranked among companies with meaningful ROA % only.
BIVV' s ROA % Range Over the Past 10 Years
Min: -191.45  Med: 25.49 Max: 84.69
Current: 84.69
-191.45
84.69
ROC (Joel Greenblatt) % 125.00
BIVV's ROC (Joel Greenblatt) % is ranked higher than
94% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. BIVV: 125.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIVV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -274.99  Med: 31.23 Max: 125
Current: 125
-274.99
125
GuruFocus has detected 3 Warning Signs with Bioverativ Inc $BIVV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIVV's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BIVV Guru Trades in

BIVV Guru Trades in

Q4 2016

BIVV Guru Trades in Q4 2016

John Hussman 175 sh (unchged)
Mairs and Power 513 sh (unchged)
First Eagle Investment 128,513 sh (unchged)
Eric Mindich 163,941 sh (unchged)
Ron Baron 3,313 sh (unchged)
Ronald Muhlenkamp 11,640 sh (unchged)
David Dreman 301 sh (unchged)
Ken Fisher 50,944 sh (unchged)
Frank Sands 1,289,455 sh (unchged)
Mario Gabelli 936 sh (unchged)
Vanguard Health Care Fund 1,920,902 sh (unchged)
Joel Greenblatt 120,156 sh (unchged)
Jim Simons 353,748 sh (unchged)
HOTCHKIS & WILEY 143,400 sh (unchged)
PRIMECAP Management 7,792,194 sh (unchged)
Andreas Halvorsen 959,406 sh (unchged)
John Buckingham 8,467 sh (unchged)
Lee Ainslie 5,440 sh (unchged)
Murray Stahl 3,328 sh (unchged)
Jeff Auxier 12,653 sh (unchged)
Richard Snow 96,181 sh (unchged)
Steven Cohen 26,771 sh (unchged)
John Paulson 26,100 sh (unchged)
Paul Tudor Jones 3,908 sh (unchged)
John Burbank 2,952 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 83,250 sh (unchged)
» More
Q1 2017

BIVV Guru Trades in Q1 2017

Jeff Ubben 8,476,892 sh (New)
Columbia Wanger 473,000 sh (New)
Paul Tudor Jones 705,824 sh (+17961.00%)
Jeff Auxier 24,179 sh (+91.09%)
First Eagle Investment 157,035 sh (+22.19%)
Ken Fisher Sold Out
John Paulson Sold Out
Vanguard Health Care Fund Sold Out
Lee Ainslie Sold Out
Murray Stahl Sold Out
Andreas Halvorsen Sold Out
John Buckingham Sold Out
Steven Cohen Sold Out
HOTCHKIS & WILEY Sold Out
Frank Sands Sold Out
Jim Simons Sold Out
Mario Gabelli Sold Out
Mairs and Power Sold Out
Ron Baron Sold Out
Eric Mindich Sold Out
John Burbank Sold Out
David Dreman Sold Out
John Hussman Sold Out
PRIMECAP Management 7,741,094 sh (-0.66%)
Ronald Muhlenkamp 11,543 sh (-0.83%)
Joel Greenblatt 109,907 sh (-8.53%)
Richard Snow 13,850 sh (-85.60%)
Eaton Vance Worldwide Health Sciences Fund 77,284 sh (-7.17%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIVV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:IONS, NAS:ALNY, NAS:TSRO, NAS:UTHR, NAS:KITE, NAS:SGEN, NAS:EXEL, NAS:CLVS, NAS:TECH, NAS:NBIX, NAS:BLUE, NAS:PTLA, NAS:ACAD, NAS:PBYI, NAS:ICPT, NAS:NKTR, NAS:SAGE, NAS:JUNO, NAS:AGIO, NYSE:XON » details
Traded in other countries:50B.Germany, BIVV.Mexico,
Headquarter Location:USA
Bioverativ Inc is a biotechnology company. It is engaged in the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets ELOCTATE and ALPROLIX products.

Bioverativ is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT-009 (part of the pending acquisition of True North) in cold agglutinin disease and other preclinical drug candidates.

Ratios

vs
industry
vs
history
PE Ratio 18.86
BIVV's PE Ratio is ranked higher than
73% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BIVV: 18.86 )
Ranked among companies with meaningful PE Ratio only.
BIVV' s PE Ratio Range Over the Past 10 Years
Min: 14.74  Med: 16.97 Max: 18.86
Current: 18.86
14.74
18.86
Forward PE Ratio 24.15
BIVV's Forward PE Ratio is ranked lower than
55% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. BIVV: 24.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.86
BIVV's PE Ratio without NRI is ranked higher than
74% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. BIVV: 18.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIVV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.74  Med: 16.97 Max: 18.86
Current: 18.86
14.74
18.86
PB Ratio 11.67
BIVV's PB Ratio is ranked lower than
85% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BIVV: 11.67 )
Ranked among companies with meaningful PB Ratio only.
BIVV' s PB Ratio Range Over the Past 10 Years
Min: 9.12  Med: 10.51 Max: 11.67
Current: 11.67
9.12
11.67
PS Ratio 7.15
BIVV's PS Ratio is ranked higher than
63% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. BIVV: 7.15 )
Ranked among companies with meaningful PS Ratio only.
BIVV' s PS Ratio Range Over the Past 10 Years
Min: 5.58  Med: 6.43 Max: 7.15
Current: 7.15
5.58
7.15
Price-to-Free-Cash-Flow 21.40
BIVV's Price-to-Free-Cash-Flow is ranked higher than
62% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. BIVV: 21.40 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIVV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.72  Med: 19.25 Max: 21.4
Current: 21.4
16.72
21.4
Price-to-Operating-Cash-Flow 18.98
BIVV's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. BIVV: 18.98 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIVV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.82  Med: 17.07 Max: 18.98
Current: 18.98
14.82
18.98
EV-to-EBIT 19.18
BIVV's EV-to-EBIT is ranked higher than
57% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. BIVV: 19.18 )
Ranked among companies with meaningful EV-to-EBIT only.
BIVV' s EV-to-EBIT Range Over the Past 10 Years
Min: 14.7  Med: 17.1 Max: 19.18
Current: 19.18
14.7
19.18
EV-to-EBITDA 16.50
BIVV's EV-to-EBITDA is ranked higher than
56% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BIVV: 16.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIVV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.7  Med: 14.7 Max: 16.5
Current: 16.5
12.7
16.5
Current Ratio 4.90
BIVV's Current Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. BIVV: 4.90 )
Ranked among companies with meaningful Current Ratio only.
BIVV' s Current Ratio Range Over the Past 10 Years
Min: 4.03  Med: 4.9 Max: 5.82
Current: 4.9
4.03
5.82
Quick Ratio 4.24
BIVV's Quick Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. BIVV: 4.24 )
Ranked among companies with meaningful Quick Ratio only.
BIVV' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.69 Max: 4.24
Current: 4.24
1.21
4.24
Days Inventory 261.25
BIVV's Days Inventory is ranked lower than
82% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. BIVV: 261.25 )
Ranked among companies with meaningful Days Inventory only.
BIVV' s Days Inventory Range Over the Past 10 Years
Min: 261.25  Med: 943 Max: 1488.29
Current: 261.25
261.25
1488.29
Days Sales Outstanding 55.20
BIVV's Days Sales Outstanding is ranked higher than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. BIVV: 55.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIVV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.2  Med: 61.5 Max: 183.04
Current: 55.2
55.2
183.04
Days Payable 21.73
BIVV's Days Payable is ranked lower than
77% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. BIVV: 21.73 )
Ranked among companies with meaningful Days Payable only.
BIVV' s Days Payable Range Over the Past 10 Years
Min: 19.49  Med: 74.52 Max: 143.05
Current: 21.73
19.49
143.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 46.49
BIVV's Price-to-Net-Cash is ranked lower than
91% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. BIVV: 46.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BIVV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 40.04  Med: 40.04 Max: 46.49
Current: 46.49
40.04
46.49
Price-to-Net-Current-Asset-Value 14.63
BIVV's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. BIVV: 14.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIVV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.61  Med: 12.61 Max: 14.63
Current: 14.63
12.61
14.63
Price-to-Tangible-Book 12.77
BIVV's Price-to-Tangible-Book is ranked lower than
81% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BIVV: 12.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIVV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 11.01  Med: 11.01 Max: 12.77
Current: 12.77
11.01
12.77
Price-to-Median-PS-Value 1.11
BIVV's Price-to-Median-PS-Value is ranked lower than
58% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BIVV: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIVV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.96  Med: 0.96 Max: 1.11
Current: 1.11
0.96
1.11
Price-to-Graham-Number 3.27
BIVV's Price-to-Graham-Number is ranked lower than
55% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. BIVV: 3.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIVV' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.82  Med: 2.82 Max: 3.27
Current: 3.27
2.82
3.27
Earnings Yield (Greenblatt) % 5.22
BIVV's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. BIVV: 5.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIVV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.22  Med: 5.8 Max: 6.8
Current: 5.22
5.22
6.8

More Statistics

Revenue (TTM) (Mil) $954.80
EPS (TTM) $ 3.35
Short Percentage of Float3.44%
52-Week Range $40.99 - 63.48
Shares Outstanding (Mil)108.16

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,082 1,203 1,302
EPS ($) 2.58 2.83 3.25
EPS without NRI ($) 2.58 2.83 3.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-0.10%
Dividends per Share ($)
» More Articles for NAS:BIVV

Headlines

Articles On GuruFocus.com
Seeking Value in Biotech: Bioverativ Jun 29 2017 
Where to Find Value in a Lofty Market Jun 16 2017 
Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001, a novel, lo Jun 14 2017 
Jeff Ubben Buys 1, Sells 1 in 1st Quarter May 24 2017 

More From Other Websites
Could Biogen Spinoff Bioverativ Have A Blockbuster On Its Hands? Jul 10 2017
Cowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up Jul 10 2017
Bioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017 Jul 07 2017
New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care Jul 06 2017
Bioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017... Jul 06 2017
3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher Jul 05 2017
Bioverativ Completes Acquisition of True North Therapeutics Jun 28 2017
How President Trump Has Sent Biotech Stocks Soaring Jun 23 2017
After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Jun 22 2017
Which Stocks Are Showing Rising Relative Strength? Jun 22 2017
New Strong Sell Stocks for June 20th Jun 20 2017
Kennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day Jun 16 2017
ETFs with exposure to Bioverativ, Inc. : June 15, 2017 Jun 15 2017
Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001, a novel,... Jun 14 2017
Bioverativ, Inc. breached its 50 day moving average in a Bearish Manner : BIVV-US : June 13, 2017 Jun 13 2017
Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat... Jun 12 2017
Breakout Watch: Top Funds Buy This Biotech IPO With 196% Growth Jun 08 2017
One Insider Just Bought $65 Million Worth of This Expensive Biotech Stock Jun 07 2017
Bioverativ to Present at the Jefferies 2017 Healthcare Conference Jun 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}